Clinical trial · Interventional
A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia
Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia
NCT02975869CI-TRIAL-00104419completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study is evaluating the impact a collaborative palliative care and oncology team will have on the quality of life, symptoms, mood, and end of life outcomes of patients with acute myeloid leukemia (AML). Palliative care is a medical specialty focused on lessening (or "palliating") symptoms and assisting in coping with serious illness.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Palliative Care | Other | — | UNRESOLVED |
| Standard Leukemia Care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Standard Leukemia Care
- description
- Standard Leukemia care
- interventionNames
- Other: Standard Leukemia Care
- type
- EXPERIMENTAL
- label
- Collaborative Palliative and Oncology Care
- description
- Collaborative care from Palliative Care and Leukemia will be given
- interventionNames
- Other: Palliative Care
Primary outcomes (1)
- measure
- Comparison of Patients' quality of life as measured by (FACT-Leukemia) Score at Week-2 Between Study Arms
- timeFrame
- 2 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Hospitalized patients with high-risk AML, defined as: * Newly diagnosed patients with AML ≥ 60 years of age * Newly diagnosed AML with antecedent hematologic disorder * Newly diagnosed therapy-related AML * Relapsed AML * Primary refractory AML Exclusion Criteria: * Patients already receiving palliative care * Major psychiatric illness or comorbid conditions prohibiting compliance with study procedures. * A diagnosis of acute promyelocytic leukemia (APML)
References
Publications (2)
- DERIVEDJensen-Battaglia M, Sohn MB, Consagra W, Wang Y, Zhang Z, LoCastro M, Davis J, Buettner K, Mortaz S, El-Jawahri AR, Loh KP. Trajectories of physical well-being among adults with acute myeloid leukemia. Blood Adv. 2024 Jun 11;8(11):2612-2621. doi: 10.1182/bloodadvances.2023011804. PMID 38429079
- DERIVEDEl-Jawahri A, LeBlanc TW, Kavanaugh A, Webb JA, Jackson VA, Campbell TC, O'Connor N, Luger SM, Gafford E, Gustin J, Bhatnagar B, Walker AR, Fathi AT, Brunner AM, Hobbs GS, Nicholson S, Davis D, Addis H, Vaughn D, Horick N, Greer JA, Temel JS. Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2021 Feb 1;7(2):238-245. doi: 10.1001/jamaoncol.2020.6343. PMID 33331857